Bibliography
- Williams RJ. Discontinued drugs in 2011: oncology drugs. Expert Opin Investig Drugs 2013;22(1):9–34
- Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;3):203–14
- Available from: http://abstract.asco.org/AbstView_114_98676.html
- Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010;10(7):514–23
- Workman P. How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003;9(11):891–902
- Morgan P, Van Der Graff P, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Disc Today 2012;17(9-10):419–24
- Borden C, Dowlati A. Phase I trials of targeted anticancer drugs: a need to refoucus. Nat Rev Drug Discov 2012;11(12):889–90
- Roth B, Krilov L, Adams S, et al. Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol 2013;31(1):131–61
- Mullard A. 2012 FDA drug approvals. Nat Rev Drug Discov 2013;12(2):87–90
- Ehmann F, Amati M, Salmonson T, et al. Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitude. Clin Pharm Ther 2013;93(5):425–32
- Available from: http://www.businesswire.com/news/home/20120711006365/en/Verastem-Acquires-Clinical-Stage-FAK-Inhibitor-Pfizer
- Available from: http://www.prnewswire.com/news-releases/vlst-corporation-announces-in-licensing-agreement-with-pfizer-for-anti-cd40-monoclonal-antibody-168130076.html
- Available from: http://www.ncats.nih.gov/research/reengineering/rescue-repurpose/therapeutic-uses/projects-2013.html